-
Mashup Score: 0Clinical Quiz: ALLEGRO and Ritlecitinib for Alopecia Areata - 1 day(s) ago
HCPLive is a comprehensive clinical news and information portal that provides physicians with up-to-date specialty and disease-specific resources designed to help them provide better care to patients. At HCPLive, you will find breaking news, video interviews with physician experts, in-depth conference coverage, finance and practice management updates, insight and analysis from physician contributors, and more.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1
These data highlight the effectiveness of long-term ritlecitinib treatment among those with alopecia areata and significant scalp hair loss.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
ICYMI: Ritlecitinib shows efficacy in #AlopeciaAreata patients with ≥25% scalp hair loss, achieving significant hair regrowth & patient-reported improvements. The ALLEGRO-LT study focused on those with alopecia totalis and universalis. View more here 👇 https://t.co/0dgGRNxXy2
-
-
Mashup Score: 0Alopecia Areata Risk in Patients With IBD Tied to Anti-TNF Use - 3 month(s) ago
Alopecia areata was more likely to develop in patients with inflammatory bowel disease (IBD) who were taking anti–tumor necrosis factor (TNF) therapy at the onset of the condition.
Source: www.ajmc.comCategories: General Medicine News, General Journals & SocietTweet-
#Alopeciaareata was more likely to develop in patients with inflammatory bowel disease (IBD) who were taking anti–tumor necrosis factor (TNF) therapy at the onset of the condition: https://t.co/Pk0pCyKpcS https://t.co/AWgiOohbLj
-
-
Mashup Score: 0Expert Insights on Deuruxolitinib for Alopecia Areata - 6 month(s) ago
Arash Mostaghimi, MD, MPA, MPH, assistant professor of dermatology, director of the inpatient dermatology consult service, and codirector of the Complex Medical Dermatology Fellowship at Brigham & Women’s Hospital, discusses the recent FDA approval of deuruxolitinib for the treatment of moderate to severe alopecia areata.
Source: www.ajmc.comCategories: General Medicine News, PayerTweet-
Tune in as Dr Arash Mostaghimi / @AMostaghimi of Brigham & Women's Hospital discusses the development and approval of deuruxolitinib for moderate to severe #alopeciaareata (AA). Learn more: https://t.co/TgUauTuwmn https://t.co/g8CKVnMTwJ
-
-
Mashup Score: 2
The phase 2 study achieved the primary end point of a >30% Severity of Alopecia Tool score improvement.
Source: www.dermatologytimes.comCategories: General Medicine News, DermatologyTweet-
❗NEW: Soterios Pharma recently announced new positive topline results from its randomized, placebo-controlled, multi-dose, phase 2 clinical trial evaluating STS-01 for the treatment of mild to moderate #alopeciaareata. https://t.co/L9gcZs8rTT
-
-
Mashup Score: 2HRQoL of Patients with Alopecia Areata in Australia - 8 month(s) ago
The largest patient study across the continent found a direct link between the extent of hair loss and the negative impact on quality of life.
Source: www.dermatologytimes.comCategories: General Medicine News, DermatologyTweet-
To better understand the experiences of adults and adolescents with #alopeciaareata, researchers surveyed 337 patients on their health-related quality of life, with questions focusing on symptom severity, psychosocial wellbeing, and productivity. https://t.co/2TkIssxQS4
-
-
Mashup Score: 0Oral JAK Inhibitors, Steroids Do Not Significantly Differ in Alopecia Hair Regrowth - 8 month(s) ago
A systematic review presented at AAPA 2024 showed insignificant differences in treatment outcomes between oral JAK inhibitors and oral steroids based on alopecia outcomes like SALT.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
In a recent study, oral JAK inhibitors and corticosteroids were consistent with one another in treatment outcomes for #AlopeciaAreata. Want to learn more? View our summary here: https://t.co/zfXHd0kU5K
-
-
Mashup Score: 4Several Barriers Linked to Hindered Access of JAKi Therapy in Patients, Particularly Non-White, With Alopecia Areata - 9 month(s) ago
These challenges may exacerbate racial inequities in care access and quality, according to a new study.
Source: www.dermatologytimes.comCategories: General Medicine News, DermatologyTweet-
Patients with #alopeciaareata endure various challenges when attempting to obtain Janus kinase inhibitor therapy, and these challenges may exacerbate racial inequities in care access and quality, according to a new study. https://t.co/01Ie9lol2B
-
-
Mashup Score: 0Alopecia Areata Impacts Patient Perception, Quality of Life - 10 month(s) ago
Patients with alopecia areata (AA) often perceive their hair loss as more severe than dermatologists do, leading to increased emotional and social problems. This study highlights the importance of understanding patient perception for better treatment and improved quality of life.
Source: www.ajmc.comCategories: General Medicine News, General HCPsTweet-
Patients with #AlopeciaAreata often perceive their hair loss as more severe than dermatologists do, leading to increased emotional and social problems. Read more: https://t.co/q1Xb5WVf2D https://t.co/gZlkfMZOTu
-
-
Mashup Score: 1Gender Differences, Disease Severity, Income Disparities Drive Financial Burden in AA - 11 month(s) ago
Women with alopecia areata (AA), especially those with severe symptoms and lower income, face significant financial burden managing the condition.
Source: www.ajmc.comCategories: General Medicine News, General HCPsTweet-
Women with #AlopeciaAreata (AA), especially those with severe symptoms and lower income, face significant financial burden managing the condition, a study finds. Read here! https://t.co/poEeRF3qAY https://t.co/i0FWJfuWH5
-
In the latest HCPLive Clinical Quiz, you can test your awareness of the June 2023 approval of ritlecitinib, the 1st treatment specifically for adolescents/young adults with severe #AlopeciaAreata. The quiz focuses on the landmark phase 2b/3 ALLEGRO trial: https://t.co/YpSjTVL5vt